A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. - Wikidata - awgldk - TriplyDB

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.

http://www.wikidata.org/entity/Q37780473

about

Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients.

P2860

Q34493523-9B53524A-8332-4277-ADAB-AE4FDA8AC211 Q35996020-0198733C-96C4-4573-8EDF-F8CFBBB08C66

P2860

A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.

http://www.wikidata.org/entity/Q37780473

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@en

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@nl

type

label

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@en

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@nl

prefLabel

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@en

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@nl

P1433

Q37780473-36137F71-A637-4B32-8DFA-2F6EDF3FAF45

P1476

Q37780473-5FCB66D2-552E-4946-B021-BC372D901CAC

P2093

Q37780473-2230A86C-77A1-42D8-A405-A54916C5F176

Q37780473-2803C596-4262-4F00-8193-99A6787197F5

Q37780473-34054CE1-489F-44CE-A77F-26880A0364C5

Q37780473-46828936-B149-423C-8BD1-447E6938DF78

Q37780473-51835F37-D304-458A-BFDB-4E0509B1FF54

Q37780473-94483434-2E8B-4A6D-A39E-0F133AF4764E

Q37780473-9C216469-126A-4D5C-B62D-D5DD9F68B32B

Q37780473-A1C6DACD-560C-4D77-8AA4-D546DEAF32F5

P2860

Q37780473-0276F2F3-62C3-4F5B-B955-DC6EB982109E

Q37780473-08D6C208-A3B5-4342-A567-2614F6F857DA

Q37780473-0B9B9C11-D90D-49F0-8153-6A6A92570412

Q37780473-142D3303-5E1F-4DEC-AA42-26DF4DAAF9D4

Q37780473-239EA721-F675-4173-BE5B-0949B1285329

Q37780473-373A557B-50B6-4F91-8461-B8989829A3B3

Q37780473-3A028C6B-7B3A-4A30-8CC9-9E39677D1E54

Q37780473-50740267-4B76-4166-9B56-CAB532C23258

Q37780473-51EA2FAD-F7FE-4736-B498-0D24A4452BEA

Q37780473-63774CD6-5266-40D9-8636-1AB356DEEA37

P2888

Q37780473-FCCD2D88-B5F2-41B4-AFE6-C4ACFDB337A6

P304

Q37780473-E04883B2-6F90-4F75-92A6-3B016EF190EB

P31

Q37780473-49234E3A-EFDD-4C3A-86E2-75563635F1A7

P356

Q37780473-58FDFC78-7293-4E3A-8097-C2BC5EFDF1D7

P433

Q37780473-7ADEDE1A-7E64-4A80-9B85-C1BE511A731F

P478

Q37780473-EE49C877-4747-4B53-9E1A-842B93E11412

P50

Q37780473-25BFD97A-8BAF-4AFC-ACE6-886C107248F1

Q37780473-ADE9BC4D-332D-41A5-B43D-AA044A677908

P577

Q37780473-B1015AC7-4C4E-4AD3-B25F-77A9E24B9ACE

P698

Q37780473-23E54E54-BB2F-4364-95B1-59B011AF1BE0

P356

S00280-010-1416-8

P1433

Cancer Chemotherapy and Pharmacology

P1476

A phase II and pharmacokinetic ...... nced gastric cancer in Taiwan.

@en

P2093

Jacqueline Whang-Peng

http://www.w3.org/2001/XMLSchema#string

Jen-Shi Chen

http://www.w3.org/2001/XMLSchema#string

Li-Tzong Chen

http://www.w3.org/2001/XMLSchema#string

Po-Min Chen

http://www.w3.org/2001/XMLSchema#string

Ruey-Kuen Hsieh

http://www.w3.org/2001/XMLSchema#string

Tsu-Yi Chao

http://www.w3.org/2001/XMLSchema#string

Tzeon-Jye Chiou

http://www.w3.org/2001/XMLSchema#string

Yee Chao

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

The National Cancer Data Base report on gastric carcinoma.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

Current status and future prospects of chemotherapy for metastatic gastric cancer: a review.

P2888

s00280-010-1416-8

P304

1281-1289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1416-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20714726

http://www.w3.org/2001/XMLSchema#string